atorvastatin has been researched along with Scleroderma, Systemic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Raya, A; Abou-Raya, S; Helmii, M | 1 |
| Kaburaki, J; Kuwana, M; Okazaki, Y | 1 |
| Anderson, M; Blann, A; Herrick, AL; Moore, TL; Murray, A; Sadik, HY; Vail, A | 1 |
| Alekperov, RT; Aleksandrova, EN; Anan'eva, LP; Korzeneva, EG; Novikov, AA | 1 |
| Ikeda, Y; Kaburaki, J; Kawakami, Y; Kuwana, M; Okazaki, Y; Yasuoka, H | 1 |
| Clancy, RM | 1 |
2 trial(s) available for atorvastatin and Scleroderma, Systemic
| Article | Year |
|---|---|
Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Topics: Atorvastatin; Double-Blind Method; Female; Fingers; Health Status; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pain; Pain Measurement; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Surveys and Questionnaires; Treatment Outcome | 2008 |
Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Scleroderma, Systemic; Time Factors; Vasodilation; Young Adult | 2010 |
4 other study(ies) available for atorvastatin and Scleroderma, Systemic
| Article | Year |
|---|---|
Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cell Count; Cell Separation; Disease Progression; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Flow Cytometry; Fluorescent Antibody Technique; Health Status; Heptanoic Acids; Humans; Immunoprecipitation; Middle Aged; Prospective Studies; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Stem Cells; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
[Pleiotropic effects of statins in systemic sclerosis].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cytokines; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Young Adult | 2011 |
Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.
Topics: Adult; Aged; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles; Scleroderma, Systemic | 2006 |
Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells?
Topics: Arteries; Atorvastatin; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Scleroderma, Systemic; Vasodilation | 2006 |